Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus co-infection and interferon treatment.
Zampino, Rosa; Marrone, Aldo; Durante Mangoni, Emanuele; Santarpia, Lucio; Sica, Antonello; Tripodi, Marie-Francoise; Utili, Riccardo; Ruggiero, Giuseppe; Adinolfi, Luigi Elio.
J Med Virol
; 73(1): 33-7, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15042645
CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV.
Evaluation of Temporal Virological Responses to Interferon-α-2b plus Ribavirin among Genotype 3a Hepatitis C Virus-Infected Patients.
Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.
Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
[Immunogenetic factors of interaction of hepatitis C virus and human and possibilities of development of therapeutic tactic].
Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection.
Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3.
Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation.
The hepatitis C revolution part 1: antiviral treatment options.